

Amendments

In accordance with 37 CFR §1.121 and 37 CFR §1.116, please amend the above-identified application as set forth below.

Amendments to the Claims:

Please amend the claims as set forth below.

Claims 1-11 (Cancelled)

12. (Previously presented) A method of treating ocular disorders involving angiogenesis, comprising the steps of:
 - providing a trans-scleral drug delivery device comprising:
 - an insert stabilizer for attachment to a scleral surface and having an interlock opening and an injection port;
 - a removable and refillable implant having a reservoir adjacent the scleral surface and an interlock tab, wherein said insert stabilizer and said removable and refillable implant are removeably connectable by mating said interlock tab and said interlock opening and wherein said injection port communicates with said reservoir;
 - providing an anti-angiogenic factor;
 - introducing said anti-angiogenic factor into said reservoir;
 - attaching said insert stabilizer to the scleral surface; and
 - refilling said trans-scleral drug delivery device alternately and selectively by disengaging said removable and refillable implant from said insert stabilizer, placing a new dosage of angiogenic factor in a pellet form in said reservoir, and re-interlocking said removable and refillable implant with said insert stabilizer, and
 - injecting a new dosage of angiogenic factor in liquid form in said reservoir through the injection port.

13. (Original) The method of treating ocular disorders as set forth in claim 12, wherein the anti-angiogenic factor is carboxyamido-triazole (CAI).

14. (Previously presented) A method of treating ocular disorders involving angiogenesis, comprising the steps of:

providing a trans-scleral drug delivery device comprising:

an insert stabilizer for attachment to a scleral surface and having an interlock opening;

a removable and refillable implant having a reservoir adjacent the scleral surface and an interlock tab;

interlocking said insert stabilizer and said removable and refillable implant by connecting said interlock tab and said interlock opening;

providing a pellet of carboxyamido-triazole; and

placing said pellet in said reservoir;

attaching said insert stabilizer to the scleral surface; and

refilling said trans-scleral drug delivery device by disengaging said removable and refillable implant from said insert stabilizer, placing a second pellet of carboxyamido-triazole in said reservoir, and re-interlocking said implant with said insert stabilizer.

Claims 15-20 (Cancelled)